Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $48.75 USD
Change Today -1.43 / -2.85%
Volume 2.2M
ISIS On Other Exchanges
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Richard S. Geary Ph.D.

Senior Vice President of Development,Isis Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

As of Fiscal Year 2014


Dr. Richard S. Geary, Ph.D has been Senior Vice President of Development at ISIS Pharmaceuticals, Inc. Dr. Geary is responsible for preclinical and clinical development of antisense drugs. From August 2003 to August 2008, Dr. Geary served as Vice President, Preclinical Development at Isis Pharmaceuticals, Inc. From November 1995 to August 2003, he held various positions within the Preclinical Development department. Since joining Isis in 1995, Dr. Geary has been involved ...

Read Full Background

Corporate Headquarters*

2855 Gazelle Court
Carlsbad, California 92010

United States

Phone: 760-931-9200
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.


Texas A&M University
The University of Texas System

Other Affiliations*

Annual Compensation*

Total Annual Compensation$636,066

Stock Options*

Restricted Stock Awards$357,450
All Other Compensation$16,861
Exercised Options37,200
Exercised Options Value$1,333,433
Exercisable Options22,050
Exercisable Options Value$1,119,871
Unexercisable Options70,731
Unexercisable Options Value$2,254,144
Total Value of Options$4,707,447
Total Number of Options129,981

Total Compensation*

Total Annual Cash Compensation$652,927
Total Short Term Compensation$636,066
Other Long Term Compensation$374,311
Total Calculated Compensation$1,785,888
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $48.75 USD -1.43


Ron Cohen M.D.Founder, Chief Executive Officer, President and Director
Acorda Therapeutics, Inc.
Edward M. Kaye M.D., Ph.D.Interim Chief Executive Officer, Chief Medical Officer and Senior Vice President
Sarepta Therapeutics, Inc.
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
Stephen R. Davis J.D.Interim Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Executive Vice President
ACADIA Pharmaceuticals Inc.
John M. Maraganore M.D., Ph.D.Chief Executive Officer and Executive Director
Alnylam Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at